adMare
News
September 18 2025
Epitopea Strengthens Scientific Advisory Board with Appointment of Four World Renowned Experts in Cancer Immunology and Immunotherapy
September 17 2025
Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome
September 09 2025
Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer
September 08 2025
Thryv Therapeutics Receives FDA IND Clearance of THRV-1268 for Heart Failure and Atrial Fibrillation and Presents SGK1 Inhibition Results Combined with Jardiance in Pressure Overload Model at ESC 2025
July 10 2025
Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic
May 27 2025
Epitopea Announces Nature Cancer Paper on Novel Immunotherapy Targets in Melanoma and NSCLC
May 01 2025
Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing
April 10 2025
Two key experts joining Find Therapeutics to accelerate the development of FTX-101
February 19 2025
Epitopea Announces License and Research Collaboration Agreement with MSD to Identify CryptigenTM Tumor-Specific Antigens
December 02 2024
KisoJi Biotechnology Raises $41 Million to Advance Lead Program Into the Clinic and Deploy AI Tools Into Key Pipeline Indications
November 21 2024
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Newsletter
Stay up to date on the
latest adMare news
Vancouver Innovation Centre
2405 Wesbrook Mall
Vancouver, British Columbia, Canada
V6T 1Z3
T. 604.827.1147
Toronto Office
MaRS Centre, West Tower
661 University Ave., Suite 415
Toronto, Ontario, Canada
M5G 1M1
T. 416.673.8100
Montreal Innovation Centre
7171 Frederick-Banting
Montréal, Québec, Canada
H4S 1Z9
